PMID- 29667438
OWN - NLM
STAT- MEDLINE
DCOM- 20180528
LR  - 20180528
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 17
IP  - 5
DP  - 2018 May
TI  - The tolerability and safety profile of patiromer: a novel polymer-based potassium 
      binder for the treatment of hyperkalemia.
PG  - 525-535
LID - 10.1080/14740338.2018.1462335 [doi]
AB  - Hyperkalemia (HK) occurs often among patients with chronic kidney disease (CKD) 
      and heart failure (HF) and those treated with renin-angiotensin-aldosterone 
      system inhibitors (RAASI). Even small deviations from normal potassium levels 
      carry increased risk of mortality. Patiromer is approved for treatment of HK and 
      has been shown in clinical trials to reduce serum potassium among patients with 
      HK and comorbid conditions. Areas covered: We review pooled data from two 
      clinical trials of patiromer in patients with CKD and HK, safety of patiromer in 
      special populations, drug-drug interaction (DDI) studies, and other studies in 
      healthy volunteers. Expert opinion: Potassium must be maintained within a narrow 
      range to avoid increased risk of mortality. Patients with CKD and HF and those 
      receiving RAASI require careful monitoring of potassium levels. Patiromer 
      effectively reduces serum potassium, and gastrointestinal adverse events (AEs) 
      are the most common patiromer-associated AEs. Effective management of HK with 
      patiromer may allow use of RAASI at optimal doses as recommended by treatment 
      guidelines. Future research should examine the potential for potassium binders, 
      including patiromer, to extend use of RAASI in appropriate patient populations.
FAU - Pitt, Bertram
AU  - Pitt B
AD  - a Internal Medicine, Department of Medicine , Cardiovascular Center, University 
      of Michigan School of Medicine , Ann Arbor , MI , USA.
FAU - Garza, Dahlia
AU  - Garza D
AD  - b Medical affairs, Relypsa, Inc. , a Vifor Pharma Group Company , Redwood City , 
      CA , USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20180422
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Polymers)
RN  - 1FQ2RY5YHH (patiromer)
RN  - RWP5GA015D (Potassium)
SB  - IM
EIN - Expert Opin Drug Saf. 2018 May;17 (5):xi. PMID: 29768100
MH  - Drug Interactions
MH  - Heart Failure/complications
MH  - Humans
MH  - Hyperkalemia/*drug therapy/etiology
MH  - Polymers/adverse effects/*therapeutic use
MH  - Potassium/*blood
MH  - Randomized Controlled Trials as Topic
MH  - Renal Insufficiency, Chronic/complications
MH  - Renin-Angiotensin System/drug effects
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - congestive heart failure
OT  - diabetes mellitus
OT  - hyperkalemia
OT  - patiromer
OT  - potassium
OT  - renin-angiotensin-aldosterone system
EDAT- 2018/04/19 06:00
MHDA- 2018/05/29 06:00
CRDT- 2018/04/19 06:00
PHST- 2018/04/19 06:00 [pubmed]
PHST- 2018/05/29 06:00 [medline]
PHST- 2018/04/19 06:00 [entrez]
AID - 10.1080/14740338.2018.1462335 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2018 May;17(5):525-535. doi: 10.1080/14740338.2018.1462335. 
      Epub 2018 Apr 22.